Cyteir Therapeutics, Inc. (CYT)
After hours: 05:42PM EDT
Chart Events
Performance Outlook
| Previous Close | 16.26 |
| Open | 16.27 |
| Bid | 15.00 x 1000 |
| Ask | 15.69 x 1200 |
| Day's Range | 15.50 - 17.36 |
| 52 Week Range | 14.00 - 23.10 |
| Volume | 206,676 |
| Avg. Volume | 164,633 |
| Market Cap | 541.126M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.50 |
- Business Wire
Cyteir Therapeutics Selected to Join Russell 2000® Index
LEXINGTON, Mass., September 20, 2021--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer was added as a member of the U.S. small-cap Russell 2000® Index, effective after the US market opens on September 20, as part of the 2021 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3
- Simply Wall St.
We're Hopeful That Cyteir Therapeutics (NASDAQ:CYT) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- PR Newswire
Lightstone Ventures Raises $375 Million Fund
Lightstone Ventures today announced the closing of Lightstone Ventures III with $375 million in capital commitments, to invest in early-stage companies developing high impact therapeutics and technologies that have the potential to change patients' lives. The new fund was oversubscribed, exceeding the firm's targeted raise, and included strong support from both new and existing limited partners. With the closing of Fund III, Lightstone Ventures also announced the appointments of Christina Isacso
